ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 13 Sep 2024
Last Updated on 17 Feb 2025
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
  • Dostarlimab 500 mg concentrate for solution for infusion, in combination with carboplatin and paclitaxel, followed by dostarlimab as monotherapy for untreated mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer. Treatment with dostarlimab should be stopped at 3 years, or earlier if disease progresses.

Funding status

Dostarlimab 500 mg concentrate for solution for infusion is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 April 2025.

Clinical indications, subsidy class and MediShield Life claim limits for dostarlimab are provided in the Annex.


Dostarlimab for treating dMMR or MSI-H primary advanced or recurrent endometrial cancer (Updated 17 Feb 2025) PES Dostarlimab for treating primary advanced or recurrent endometrial cancer (Updated 17 Feb 2025)